{
    "organizations": [],
    "uuid": "40cc9eca4d92105426779efaede342bcb69ca0cf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kiadis-pharma-on-track-with-europe/brief-kiadis-pharma-on-track-with-european-regulatory-review-for-atir101-idUSFWN1R90WT",
    "ord_in_thread": 0,
    "title": "BRIEF-Kiadis Pharma On Track With European Regulatory Review For ATIR101",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 28 (Reuters) - KIADIS PHARMA NV:\n* ON TRACK WITH EUROPEAN REGULATORY REVIEW FOR ATIR101 * ‍ON TRACK TO POTENTIALLY OBTAIN A POSITIVE CHMP OPINION FOR ATIR101 IN Q4 2018\n* ‍ON TRACK TO POTENTIALLY OBTAIN (CONDITIONAL) APPROVAL FROM EUROPEAN COMMISSION IN Q1 2019 FOR ATIR101​\n* THE APPROVALS ‍WOULD ALLOW FOR A EUROPEAN LAUNCH IN H2 2019​\n* ‍IS CONDUCTING A PHASE 3 TRIAL WITH ATIR101 ACROSS EUROPE AND NORTH AMERICA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-03-28T13:05:00.000+03:00",
    "crawled": "2018-03-29T16:13:58.044+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "kiadis",
        "pharma",
        "nv",
        "track",
        "european",
        "regulatory",
        "review",
        "atir101",
        "track",
        "potentially",
        "obtain",
        "positive",
        "chmp",
        "opinion",
        "atir101",
        "q4",
        "track",
        "potentially",
        "obtain",
        "conditional",
        "approval",
        "european",
        "commission",
        "q1",
        "approval",
        "allow",
        "european",
        "launch",
        "h2",
        "conducting",
        "phase",
        "trial",
        "atir101",
        "across",
        "europe",
        "north",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}